ENTITY
YiChang HEC ChangJiang Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical (1558 HK)

137
Analysis
Health Care • China
YiChang HEC ChangJiang Pharmaceutical develops, manufactures, and sells pharmaceutical products, focusing on anti-viral, endocrine and metabolic, and cardiovascular diseases. Key products include Kewei (oseltamivir phosphate), Oumeining (telmisartan), and Ertongshu (benzbromarone). The company was founded in 2001 and is headquartered in Dongguan, China.
more
bullish•Great Wall Motor
•08 Apr 2019 16:42

HK Connect Discovery Weekly: Air China and Great Wall Motor (2019-04-04)

In our Discover HK Connect series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed by...

Logo
823 Views
Share
bullish•Tencent
•04 Mar 2019 13:48

HK Connect Discovery - February Snapshot (Tencent, COFCO Meat)

This is a monthly version of our HK Connect Weekly note, in which I highlight Hong Kong-listed companies leading the southbound flow weekly. Over...

Logo
552 Views
Share
bullish•Sands China
•25 Feb 2019 12:30

HK Connect Discovery Weekly: Geely, Great Wall Motor and Sands China (2019-02-22)

In our Discover HK Connect series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed by...

Logo
688 Views
Share
bullish•Geely Auto
•18 Feb 2019 12:02

HK Connect Discovery Weekly: China Tower, Geely, COFCO Meat (2019-02-15)

In our Discover HK Connect series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed by...

Logo
1k Views
Share
bullish•CRRC
•28 Jan 2019 15:45

HK Connect Discovery Weekly: CRRC, Car Inc/UCar (2019-01-25)

In our Discover HK Connect series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as analyzed by...

Logo
672 Views
Share
x